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Purpose: We have examined the impact of sample processing time delay, temperature, and
the addition of protease inhibitors (PIs) on the urinary proteome and peptidome, an important
aspect of biomarker studies.
Experimental design: Ten urine samples from patients with varying pathologies were each
divided and PIs added to one-half, with aliquots of each then processed and frozen immediately,
or after a delay of 6 h at 4C or room temperature (20–22C), effectively yielding 60 samples in
total. Samples were then analyzed by 2D-PAGE, SELDI-TOF-MS, and immunoassay.
Results: Interindividual variability in profiles was the dominant feature in all analyses.Minimal
changes were observed by 2D-PAGE as a result of delay in processing, temperature, or PIs and
no changes were seen in IgG, albumin, 2-microglobulin, or 1-microglobulin measured by
immunoassay. Analysis of peptides showed clustering of some samples by presence/absence
of PIs but the extent was very patient-dependent with most samples showing minimal effects.
Conclusions and clinical relevance: The extent of processing-induced changes and the benefit
of PI addition are patient- and sample-dependent. A consistent processing methodology is
essential within a study to avoid any confounding of the results.
Keywords:
Peptides / Protease inhibitor / Proteomics / Temperature / Urine
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
There is considerable interest in the use of urine for
biomarker studies, particularly in urological diseases since
it potentially contains proteins secreted or shed directly from
the kidney, bladder, or prostate at higher concentrations
than in the peripheral circulation, in addition to products
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of glomerular filtration from the systemic circulation. Addi-
tionally, it can be collected noninvasively in relatively large
quantities, is less complex than serum, repeated sampling
is possible for monitoring, and the majority of proteins are
soluble [1–3]. However, analytical challenges include its di-
lute nature and high salt content, and its marked biological
variability, being influenced by a variety of factors including
hydration state, diet, timing, exercise, gender, and age [1–3].
Relatively few urinary biomarkers have been approved by
the FDA with examples including nuclear matrix protein 22
(NMP22) and bladder tumor associated antigen (complement
∗These authors contributed equally to this work.
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Clinical Relevance
Urine is often used for biomarker discovery studies
in diseases affecting the urinary tract. However, rel-
atively few studies have investigated the potential
impact of pre-analytical factors on urinary proteins
and most such studies have used urine from healthy
controls. This study has investigated the effects of
processing time, temperature, and use of PIs on pro-
teins and peptides in urine using 2D-PAGE andSELDI,
and importantly using urine samples from patients
from different disease groups. Overall, our conclu-
sions are that the dominant factors are the disease
and interpatient differences but that changes in pep-
tides (and to a lesser extent proteins) can occur to a
limited and variable extent during sample process-
ing/storage depending on the patient, particularly in-
volving proteolytic activity. It is important that within
studies, a consistent sample processing methodol-
ogy is employed in order to allow robust unbiased
conclusions to be drawn, and that the stability of any
potential identified biomarkers for the specific pro-
cessing conditions is checked.
factorH related protein/complement factorH) for use in blad-
der cancer surveillance [4] and there is nowan enhanced effort
to use proteomic technologies to identify new biomarkers.
Recent proteomic studies employing extensive fractionation
describe more than 2300 proteins in urine [5], and >100 000
different peptides with at least 5000 occurring in >20% of
patients in any disease group [6]. Such datasets provide a
valuable resource with many available online (linked from
www.urineproteomics.org). The potential of these types of
study is now beginning to be recognized, as illustrated by the
CKD273 peptide classifier for type 2 diabetic nephropathy [7].
Several studies describe the development of standardized
urine proteomic analysis methodologies for different plat-
forms with a consideration of the various technical aspects
(e.g. [8–12]). However, although the potential impact of var-
ious pre-analytical factors during clinical sample processing
on proteomic studies is increasingly being recognized [13],
relatively few systematic studies have been undertaken us-
ing urine. Initiatives such as the “Biospecimen Reporting for
Improved Study Quality” [14] provide guidance generically
for some of the aspects to consider recording with studies
involving clinical samples and a review has highlighted some
of the areas that require further examination for urinary-
based studies, including the effects of protease inhibitors (PI)
and processing/storage conditions [15]. Various studies have
investigated such aspects, but these are limited in mostly
having used samples from healthy controls, often from only
one or two individuals and often only analyzing or reporting
relatively gross readouts, for example numbers of proteins
identified. With these caveats, studies using LC-MS/MS have
reported no significant effects of storage at room tempera-
ture (RT) for up to 24 h [16] and no impact of PI during
frozen storage as assessed by either LC-MS/MS or 2D-PAGE
[9, 12]. Analysis of peptides by MALDI/SELDI has shown
temperature-dependent effects with changes if stored at 4C
compared with −20C [11] or 6 h at 25C but not 4C [17],
small differences between 4C and RT but increasing at 72 h
compared with 1 or 6 h [18], and a decrease in the number
of peaks at RT, which was not seen in the presence of PI
until time points greater than 2 h [19]. Using CE-MS, leaving
urine samples at 4C for 24 h or RT for 6 h did not alter the
statistical spread of results or result in altered classification
of the samples in the model [10].
In this study, we have systematically examined the effects
of sample processing time, temperature, and the presence
or absence of PI on urine samples, parameters highlighted
as requiring further study to contribute to the evidence
underlying recommendations for standardized protocols
[15]. Proteins and peptides were examined globally using
2D-PAGE and SELDI-TOF-MS, respectively, in addition
to immunoassay of the specific proteins, retinol-binding
protein, 2-microglobulin (2M), 1-microglobulin (1M),
IgG, and albumin. Importantly, samples used were from
patients with a spectrum of renal/urological conditions as
different pathologies may impact potentially more than
would be seen in urine samples from healthy controls.
Such studies examining pre-analytical factors are critically
important in the interpretation of biomarker studies, both
in terms of allowing comparisons between studies and in
providing evidence to drive the development of standardized
protocols.
2 Materials and methods
2.1 Materials
Materials were purchased from the following suppliers
as indicated: CyDyeTM Cy5 DIGE Fluor minimal dye,
ImmobilineTM DryStrip IPG strips (pH 3–10NL, 24 cm; GE
Healthcare, Amersham, UK); CHAPS (Calbiochem, Middle-
sex, UK); all consumables associated with SELDI (Bio-Rad
Laboratories, Hemel Hempstead, UK); ACN LC-MS grade
(Fisher Scientific UK Ltd, Loughborough, UK); Complete
Mini, EDTA-free, PI cocktail tablets (Roche, Lewes, UK);
acetic acid (VWR, Leicestershire, UK); urea (MP Biomedi-
cals, Strasbourg, France); TFA (ThermoScientific, Horsham,
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Table 1. Patient characteristics and urine biochemistry
Patient Gender Age Clinical scenario Creatinine Protein PCR pH Blood 1M 2M Albumin IgG
(M/F) (years) (mmol/L) (mg/mL) (mg/L) (mg/L) (mg/L) (mg/L)
Aa) M 31 19 days post-RTx 3.7 0.13 35.1 5.19 +++ 20 0.1 43 7
B M 49 29 days post-RTx 8.0 3.45 431.3 4.97 + 74 0.9 2873 114
C M 42 8 days post-RTx 1.6 0.04 25.0 6.48 Neg 11 2.2 <3 2
Da) M 31 26 days post-RTx 10.6 0.61 57.5 5.31 +++ 54 0.3 322 39
E M 56 12 days post-RTx 5.6 0.20 35.7 5.50 + 26 0.9 70 12
F M 48 Renal stones 3.6 0.16 44.4 7.25 Neg 8 0.1 <20 5
G M 62 Renal stones 6.6 0.70 106.1 6.23 Neg 11 0.5 478 48
H F 48 Renal stones 3.1 0.03 9.7 5.62 Neg 6 <0.1 <20 2
I F 71 Recurrent UTIs 4.8 0.19 39.6 5.80 Trace 17 1.5 36 17
J F 50 Recurrent UTIs 3.8 0.04 10.5 5.64 Neg <6 <0.1 <20 7
1M, 1 microglobulin; 2M, 2 microglobulin; Neg, negative; PCR, protein creatinine ratio; RTx, renal transplantation; UTI, urinary tract
infection; blood, based on dipstick reading.
a) The samples labeled as patients A and D originated from the same patient 1 wk apart.
UK); sequencing grade modified porcine trypsin (Promega,
Southampton, UK). All other chemicals were obtained from
Sigma-Aldrich (Dorset, UK), and were of analytical grade or
above. Milli-Q water was used throughout.
2.2 Urine sample collection and processing
Ten midstream urine samples were prospectively collected
from nine patients following renal transplantation or attend-
ing St. James’s University Hospital in Leeds with a variety
of benign renal/urological conditions, between October 2009
and January 2010 (Table 1). The study was approved by the
Leeds East Research Ethics committee and informed consent
was obtained. Immediately following voiding, samples were
tested for blood and protein using a dipstick (Siemens Multi-
stix, Frimley, Surrey, UK), and an aliquot removed for protein
and creatinine determination using a Siemens Advia 1800
analyzer (Siemens) in the Blood Sciences Department, Leeds
General Infirmary. After adjusting the pH to 7.0, samples
were each divided into two and PI was added to one-half (one
tablet per 25 mL urine). These two aliquots of each sample
were then further subdivided as indicated (Fig. 1) to investi-
gate the effects of processing times (immediate vs. 6 h delay)
and temperature during the delay period (4C vs. RT (in this
case 20–22C), prior to centrifugation at 2000 × g for 10 min,
and removal and storage of the urine supernatant at −80C
until analysis.
2.3 Proteomic analysis
2.3.1 Sample concentration for analysis
Urine samples were thawed at RT and concentrated by cen-
trifugal filtration according to the manufacturer’s instruc-
tions and with starting volumes depending on the pro-
tein concentration. For analysis by 2D-PAGE, 0.5–6.5 mL
of each sample was concentrated using Amicon 10 kDa
MWCO Ultra-15 filtration units with the filtrate (150–
200 L), vacuum-centrifuged for 1.5 h, and the result-
ing pellet was resuspended in DIGE lysis buffer (7 M
urea, 2 M thiourea, and 4% w/v CHAPS). For analysis
by SELDI, 0.1–1 mL of each sample was concentrated us-
ing Amicon R© 3 kDa MWCO Ultra 0.5 mL centrifugal de-
vices to a final volume of 100–200 L. Protein concentra-
tions were determined using the Bradford assay (Bio-Rad
Laboratories).
2.3.2 SELDI-TOF-MS
Peptide profiling of the 60 urine samples was undertaken us-
ing a SELDI-TOFmass spectrometer (ProteinChip R© System,
series 4000, Ciphergen, Fremont, CA, USA) and Ciphergen
ExpressTM Client software (v3.0) for data analysis. IMAC30-
Cu (immobilized metal affinity capture array with copper
surface) ProteinChipTM arrays were selected for use follow-
ing initial studies, and urine sample and matrix application
to ProteinChip arrays and data collection were performed as
previously [20, 21]. A QC sample was prepared by pooling
3 g of all 60 urine samples. All samples were analyzed blind
in triplicate and block randomized within a patient, with one
spot on each sample chip containing the pooled QC sample.
Following data extraction, duplicate profiles passing QCwere
selected for each sample analysis (with a fail rate of20–30%,
this strategy minimized reruns with analysis in duplicate be-
ing our normal practice). External mass calibration was per-
formed with a standard calibration mixture of peptides and
proteins from Ciphergen (three-parameter weighted): bovine
insulin -chain (3495.9 Da), human insulin (5807.6 Da), and
recombinant hirudin (6963.5 Da). Peaks within the range
3–10 kDa were detected using a signal/noise threshold of
2.0 (centroid fraction 10.0%), and profiles examined for peak
number and redundancy within each urine sample exposed
to various processing protocols.
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Figure 1. Schematic showing the study
design. For immunoassay and SELDI,
all ten samples each with six pro-
cessing conditions were analyzed (for
SELDI, 120 duplicate profiles were gen-
erated). For 2D-PAGE, only six of the
samples each with six processing con-
ditions were used due to volume limi-
tations and were analyzed in triplicate
creating 108 gels.
2.3.3 2D-PAGE and protein identification
Samples A, B, D, E, G, and I (the remaining samples had
insufficient volume/protein) were adjusted to 1.0 mg/mL
protein concentration and labeled individually in triplicate
with Cy5 (CyDye DIGE Fluor, minimal dye) as previously de-
scribed [22]. Labeled samples (50g per strip) were separated
by IEF using 24-cm pH 3–10NL Immobiline IPG strips prior
to electrophoresis in the second dimension on 24-cm 10%
polyacrylamide gels and fluorescence imaging. The major
central forms of albumin were allowed to saturate in scan-
ning, to improve the detection of lower abundance species,
and excluded from downstream analysis; scans were normal-
ized to the next most intense species in each image. Gel
images were analyzed using Progenesis SameSpots software
v4.5 (TotalLab, Newcastle-upon-Tyne, UK). QC analysis was
first carried out on a run-by-run basis incorporating auto-
mated image assessment in the “Image QC” module com-
bined with further multivariate analyses and visual inspec-
tion. Runs failing QC metrics were repeated and appropriate
gelswere selected for subsequent quantitative analyses. These
were done separately for each sample, with the six handling
conditions being compared in triplicate. Cropping, automatic
reference gel selection, alignment, and spot detection were
carried out, with manual correction where necessary. Spot
normalized volume data were then exported in .csv (comma-
separated values) format for statistical analysis. To allow the
different patterns to be related qualitatively for conservation
of changes, a PG240 (TotalLab) experiment containing all the
master reference maps was generated from the SameSpots
archives and used to cross-match all the patterns.
2.3.4 Immunoassay of specific urinary proteins
The specific urinary proteins, 2-microglobulin (2M), 1-
microglobulin (1M), IgG, and albumin, were determined by
the Protein Reference Unit at Sheffield Teaching Hospitals.
Briefly, 2M, IgG, and albumin were measured by immuno-
turbidimetry (Cobas Core, Roche Diagnostics, Burgess Hill,
UK), and 1M by immunonephelometry using the Behring
Nephelometric Analyzer II (Siemens). The LOD (and CV) for
the specific protein assays was as follows:1M 2.0mg/L (7%),
2M 0.2 mg/L (5%), albumin 3 mg/L (5%), and IgG 4 mg/L
(8%).
2.4 Statistical analysis
The SELDI and gel data were examined by PCA and hierar-
chical clustering analysis using a Euclidean distance metric
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Figure 2. Representative examples of the SELDI profiles of each sample.
andWard’s agglomerationmethod, for all data combined and
separately for each urine sample condition.
The effect of PI addition and processing tempera-
ture/delay on detected peaks from the SELDI-TOF spectra
was evaluated using linear mixed effects model when consid-
ering multiple patients and linear models when considering
individual patients. The linear mixed effect model can be
represented through the equation:
yijkt = + xi + zt + xizt + j + 	ijkt
A separate model was fitted for each peak, and separate
models were fitted for all samples, post-transplant samples,
and benign urological disease samples. In the model for all
samples, the response variable yijtk is the intensity value at
one peak cluster. Here, i indexes the inclusion of PI (+PI—
reference level compared with−PI), j the subject, k the repeat
number (since all combinations were run in duplicate), and
t the processing temperature (−80C—reference level com-
pared with 4C and RT). An interaction term in the model for
PI inclusion and processing temperature was also included,
that is a term that will indicate a departure from additive
effects in the model. These are the fixed effects in the model.
The random effect j in the model (j  N(0,
2)) de-
scribes a subject-specific effect and allows for the correlation
between peak intensities measured on the same subject. The
final term describes the residual variation (	ijkt  N(0,
	2)),
assumed to be uncorrelated with the other terms.
For each sample individually, linear models were
considered. These models were fitted separately for each
peak and each sample and can be represented through the
equation:
yikt = ′ + ′xi + ′zt + ′xizt + j + 	ikt
As above, i indexes the inclusion of PI (+PI, reference level
compared with −PI), k the repeat number, and t the process-
ing temperature (−80C, reference level compared with 4C
and RT). An interaction term in the model for PI inclusion
and processing temperature was also included, again to indi-
cate any departure from additive effects in the model. When
examining fixed effects from the linear mixed effects and
linear models, significance levels of 0.1% (p < 0.001) were
considered significant as an ad hoc measure to control the
false discovery rate. All analyses were undertaken in the R
environment for statistical computing (R Development Core
Team, Vienna) using the lmer() function in library(lme4) for
the linear mixed effects models [23] and lm() for the linear
models.
For the gels, linear models were employed to generate
three key datasets: (i) alterations within sample associated
with PI, independent of/across temperatures; (ii) alterations
within sample associated with temperature, independent of
PI status; and (iii) alterations within sample associated with
PI but showed a differing effect of PI across temperatures.
In the first two cases, simple cut-offs (2-fold elevation or
decrease in the linear model, p  0.05) were applied to select
spots for identification. In the third case, the target was spots
that were altered by PI more notably at higher temperatures,
so searching for degradation under harsher conditions that
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PI treatment opposed. This required a heterogeneity (p 
0.05) across temperature groups for PI effect, and a typical
(2-fold elevation or decrease in the linear model, p  0.05)
cut-off combination at RT, the group that would be expected
to be most affected. Furthermore, a simple requirement of
increasing divergence inmean fold change terms of−80C<
4C < RT was applied.
3 Results
3.1 Patient characteristics
Brief characteristics of the patients and their urinalysis results
are shown in Table 1. Elevated results formany of the analytes
are seen reflecting the different underlying disease processes
and the intended heterogeneity of the samples used in this
study.
3.2 Peptide and protein alterations
3.2.1 Peptide profiles (SELDI-TOF)
The profiles of the samples from different patients differed
markedly (Fig. 2). Overall, 228 peaks were detected across
all samples combined with average peak numbers for differ-
ent patients ranging from 156 (patient G) to 211 (patient A).
Analysis of the CVs of all peaks in the pooled QC samples in-
cluded on every chip showed a range of 23.5–109.4% with an
overall median CV of 39.3%. PCA and hierarchical clustering
analysis of data from all patient samples showed evidence of
clustering predominantly by patient and also by broad clini-
cal group (postrenal transplant or other; Fig. 3). No evidence
of clustering on the basis of processing temperature/delay
period or of technical analytical variables such as chip spot
numberwas apparent, although some indication of clustering
was seen on the basis of ±PI and when data from individual
patients were examined, samples were perfectly separated by
PI status in three of the ten patients (B, E, and I; Fig. 4).
Analysis of changes in specific peaks using lme and lm
model results and using a cut-off peak intensity of> 1, mini-
mum fold difference of 2 (based on the technical variability),
and p < 0.001 compared with the “gold standard” condition
of +PI/immediate processing (assumed to have least
proteolysis) confirmed the exploratory data analysis results
mentioned above. For example, the most pronounced effect
was seen in patient J where 56 of 182 (30.7%) peaks changed
between the immediate processing/+PI and delayed process-
ing for 6 h at RT/−PI (this patient also showed the biggest
fold changes in specific peaks as can be seen in Supporting
Figure 3. PCA (PC1 vs. PC3) and hierarchical clustering of proteomic profile obtained by SELDI considering all patients and replicate
samples. Color coding represents (A) patient (A–J), (B) addition of protease inhibitor (+PI/−PI), (C) patient status (RTx = renal transplant
or other), and (D) processing conditions (immediate processing and stored at −80C, delayed processing and stored at 4C, and delay and
stored at room temperature (RT; 20–22C)). Clustering is apparent by patient and also disease status with one patient (B) having a profile
that could be considered quite different from the others. The clustering by patient is clearer than any separation by protease inhibitor or
processing condition indicating patient heterogeneity is a more dominant factor than the manner in which a sample is processed.
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Figure 4. PCA (PC1 vs. PC3) and hierarchical clustering of proteomic profile obtained by SELDI considering samples from patients B, E, G,
and I and replicate samples. Color coding represents addition of protease inhibitor (+PI/−PI) to a sample. There is clear separation in PCA
and dendrograms by addition of protease inhibitor for three of the patients. Clear separation was not apparent when further examining
plots related to other processing conditions.
Information Fig. 1A andBwhere peakswith fold-changes of 3
and 5 are shown, although few in number). This is in marked
contrast to patients C, D, E, and G where nine peaks
(1.2%) changed across all samples/conditions using the
above criteria (Fig. 5A, Supporting Information Table 1).
Interestingly, although samples from patient E clustered
perfectly according to ±PI (Fig. 4), the changes seen did
not reach the above criteria (Fig. 5A), although if a less
stringent cut-off of 1.5-fold change was applied, the ±PI
effect started to become more apparent (Fig. 5B). This can
be explained by other factors potentially interacting with the
PI effects in some patient samples (e.g. J) and also it must be
remembered that the first three principal components only
explain on average 71% of the variance.
Although there were overlaps in the peaks affected, no
consistent pattern was apparent across patients with the
exception of the region of 6000–6600m/zwhere several peaks
increased in the absence of PI in several patients (Fig. 5A and
B, Supporting Information Table 1). Peak changes generally
in the absence of PI were fairly consistent within a patient and
almost irrespective of delay time and temperature, although
immediate processing in the absence of PI prevented some
of the changes in patients F and H. Even in the presence of
PI, delay at RT did lead to some changes in the four patients
who showed the most marked changes overall in the absence
of PI (patients B, F, I, and J), although often affecting
different peaks to those affected in the absence of PI, and
this trend can be seen more obviously when relaxing the
threshold of fold-change to 1.5× (Fig. 5B). To check for the
possibility that the presence of the PI chemicals themselves
was causing any effect on the spectra independently of their
biological action, three processed urine samples were spiked
with PI and immediately analyzed and compared with the
spectra from the same urine samples in the absence of PI.
Using a similar cut-off of twofold change and p < 0.001, no
significant difference in any peaks was found in the presence
and absence of PI (and only four peaks overall at a 1.5-fold
change) and no clustering on the basis of PI.
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Figure 5. Heatmaps showing statistically
significant changes in SELDI peak in-
tensity from “gold standard” processing
condition (+PI/immediate processing). Pa-
tients (A–J) are represented by columns
with subcolumns representing each sam-
ple processing condition (−PI/immediate
processing or ±PI delayed processing at
4C or room temperature (20–22C)). Rows
represent SELDI peaks arranged by m/z
ratio. Increases in peak intensity of (A)
twofold or greater or (B) 1.5-fold or greater,
which are significant at p < 0.001, are rep-
resented by black rectangles and similarly
significant decreases in peak intensity are
represented by white rectangles. Peakm/z
values are provided in Supporting Infor-
mation Table 1 for the twofold changes.
3.2.2 Protein profiles (2D-PAGE)
The numbers of spot features present in the final profile of
each sample are provided in Table 2, and the reference image
resulting from each analysis is shownwith pattern overlaid in
Fig. 6. Themeannumber of spots detectedwas 1082. Separate
intrapatient analyses (with the repeat time points A and D for
the same patient also being treated separately) were seen to be
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Table 2. Results from the six 2D-PAGE intrapatient analyses showing the numbers of features detected in the final profile of each feature
map, and the numbers of statistically significant alterations with each variable investigated according to the criteria in Section 2.4
Alterations Sample Conservation,
where examined
Aa) B Da) E G I
Features in profile 1117 878 1118 1219 949 1209
Target (i)
PI elevated 9 3 2 18 9 30
Conserved in at least three samples 0
Conserved in at least three different individuals 0
PI reduced 24 23 10 28 39 19
Conserved in at least three samples 5
Conserved in at least three different individuals 4
PI total 33 26 12 46 48 49
Target (ii)
4C elevated 2 19 7 15 5 4
Conserved in at least three samples 0
Conserved in at least three different individuals 0
4C reduced 2 3 2 16 1 12
Conserved in at least three samples 0
Conserved in at least three different individuals 0
4C total 4 22 9 31 6 16
RT elevated 10 9 4 11 1 3
Conserved in at least three samples 0
Conserved in at least three different individuals 0
RT reduced 12 6 9 23 2 13
Conserved in at least three samples 1
Conserved in at least three different individuals 0
RT total 22 15 13 34 3 16
Elevation, both temps 0 0 1 2 0 0
Reduction, both temps 0 0 2 11 0 5
Target (i) and (ii) combination
PI and 4C (any direction) 0 0 1 11 0 6
PI and RT (any direction) 0 1 1 15 2 11
Target (iii)
PI versus non-PI heterogeneity analysis—elevated with PI 0 0 0 2 0 0 None conserved
across patients
PI versus non-PI heterogeneity analysis—reduced with PI 0 0 2 5 10 1 None conserved
across patients
PI versus non-PI heterogeneity analysis—total 0 0 2 7 10 1 None conserved
across patients
As standard these were a 2-fold change in the linear model, with p  0.05. For the heterogeneity analyses, three criteria were applied
in the second linear model. The heterogeneity p value was 0.05 or less, there was a significant change with PI in the RT group by normal
cut-offs, and the mean fold change rose in the order −80C < 4C < RT.
a) A and D are treated as two patients but represent two samples taken from the same patient 1 wk apart.
necessary to investigate processing effects. Although the pro-
files between patients were grossly similar (Fig. 6), especially
the repeat-sampled A and D, there were many differences
in moderate to low abundance species between patients,
meaning that a key assumption of 2DE analysis, that most
species present remain unaltered, would have potentially
been violated in a single analysis comparing all the samples.
To illustrate this, such an analysis was additionally carried
out, using the six aligned image sets and cross-aligning them
further via their reference gels using visually conserved pro-
teins as landmarks, to align all 108 gels. Plotting the first two
principal components in SameSpots showed that interpatient
variation overwhelmingly dominated the separation with no
comparable level of effect of PI status or temperature (Fig. 7).
Indeed, 849 of 855 spots detected in this 108-gel experiment
were altered significantly across the six patient sample sets
by ANOVA at the 0.05 level as reported by SameSpots. This
supported the use of separate intrapatient analyses for the
discovery of alterations associated with processing. Further
supporting this, the serial samples from patient A/D (treated
as two patients) showed similar behavior and a very similar
number of spots were detected. Figure 7 shows that even
repeat sampling and analysis of the same individual is
associated with more variability than that caused by variation
in processing method. Examination by PCA of individual
patients on the basis of PI showed no apparent clustering.
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Figure 6. The reference image from each patient with the final spot pattern superimposed. (A) Patient A; (B) patient B; (C) patient D;
(D) patient E; (E) patient G; (F) patient I.
The numbers of proteins altered with processing within
each sample by the criteria described in Section 2.4 are sum-
marized in Table 2. While there were alterations with PI
and temperature in each sample and more species appeared
with the omission of PI than with its inclusion, the changes
were very small in number, few were conserved, and any
temperature-associated alterations were quite different be-
tween 4C and RT, at least at the cut-offs used, which may
reflect gradation. The five most conserved protein changes
with PI are shown in Fig. 8. Attempts to identify the proteins
associated with conserved PI-induced changes were unsuc-
cessful, presumably due to low abundance as they were not
visible on preparatory gels. There were no conserved species
altered across samples showing an increasing effect of PI
with temperature.
3.2.3 Specific proteins
Although there were marked differences in the concentra-
tions of the specific proteins, 2M, 1M, IgG, and albumin,
between samples from the different patients, no significant
differences (p < 0.05) were detected between the different
processing conditions (Supporting Information Table 2).
4 Discussion
Progress is being made in biomarker discovery stud-
ies through exploitation of the various technological
developments inMS in particular, coupledwith an increasing
realization that the impact of pre-analytical variables in clini-
cal proteomic studies can be critical [13]. Urine is increasingly
being used in biomarker studies and even without superim-
posed pathological changes, its composition varies consider-
ably physiologically due to factors such as diet, timing, exer-
cise, gender, and age [1–3]. This is also illustrated through
a recent LC-MS/MS analysis examining urine samples from
seven individuals over 3 days where in >600 identified pro-
teins, the technical variability with a median CV of 18% was
far less than that of the intra- and interindividual variability
at 48 and 66%, respectively [24]. As discussed further below,
our study also shows marked differences in protein and pep-
tide profiles between samples fromdifferent individuals, even
within similar disease groupings, illustrating the challenges
of biomarker discovery in cross-sectional comparisons where
even “background” variability is so high. Although careful
patient matching may help, it is likely that longitudinal com-
parisons of samples matched within patients, for example
pre- and postremoval removal of a cancer, may overcome
such background heterogeneity and lead to more easily iden-
tifiable disease-related changes.
However, some of the technical pre-analytical factors
are less well investigated, in particular the evidence for
whether proteolysis is an issue and addition of PI should be
advocated, and the impact of different processing/storage
conditions is still sparse [15]. A tentative standard protocol
for urine sample collection and processing has been pro-
posed by the HUPO Human Kidney and Urine Proteome
Project, for example recommending that PI addition may be
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Figure 7. PCA of all 108 gels in a single
SameSpots experiment, generated within
the software and showing the first two
eigenvectors in each case. The color key is
below each plot. (A) All 108 samples col-
ored by patient (pink=A, olive= B, green=
D, mid-blue = E, light blue = G, orange =
I); (B) by PI status; (C) by temperature. The
first two components cumulatively explain
49.57% of the total variance.
necessary for proteinuric urine samples (with further eval-
uation planned), but not for normal urine samples (http://
www.hkupp.org/Urine%20collectiion%20Documents.htm)
and storage can be either at −20 or −80C. The exception is
where exosome analysis is involved when PI addition is advo-
cated and this is also the case on the EuroProt website describ-
ing protocols for urinary exosome analysis (http://www3.
niddk.nih.gov/intramural/UroProt/collection-storage.shtml),
together with storage at −80C with significant reductions in
recovery of exosomal proteins being reported after 7 months
of storage at −20C [25].
In our study, the changes in proteins as analyzed by 2D-
PAGE were insignificant in number and did not appear to be
more prevalent in any particular set of conditions. This is also
in agreement with most previous studies at the protein level,
although some are quite limited in scope. Using SDS-PAGE
followed by LC-MS/MS to analyze urine from a healthy con-
trol left at RT for 0, 4, 8, and 24 h, no significant differences
were found in terms of the numbers of proteins detected or
mean normalized spectral counts when the 200 most abun-
dant proteins were examined in groups of 50 [16]. Similarly by
iTRAQ, no significant changes relating to PI addition were
seen in numbers or amounts of 83 proteins in urine sam-
ples from a healthy control, stored for <1 wk at −80C ±PI
[9]. PI addition has also not been recommended as neces-
sary based on 2D-PAGE evaluation, but with the caveat that
this was based on analysis of normal nonproteinuric urine
samples stored at −30 or −70C [12]. In our study involv-
ing a variety of pathological urine samples, the number of
changes seen in proteins following delays in sample process-
ing at various temperatures was small and little effects of
PI addition were seen by 2D-PAGE. Clearly, some proteins
were affected but careful validation of any findings relating to
specific proteins should involve stability studies rather than
necessarily supporting the addition of PI routinely. Examin-
ing specific proteins illustrates this, for example storage of
urine samples at 4 or 25C for 48 h prior to freezing versus
immediate processing had no effect on NGAL, cystatin C,
L-FABP, or KIM-1 but effects on IL-18 were seen, particu-
larly at 25C, although whether this was due to proteolysis
is not clear [26]. Similarly, analysis of urine samples from
pediatric diabetic patients stored at −20 versus −70C for
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Figure 8. (A) The five “most con-
served” changes altered with PI in-
dependently of temperature accord-
ing to the standard cut-offs in more
than one sample. The numbers as-
signed are those from the mas-
ter PG240 matching pattern with
changes in spots 373, 379, 685, 1191,
and 1204 being conserved in four,
three, three, three, four samples, re-
spectively, and all increased in the
absence of PI. The image is of sam-
ple E at −80C, +PI gel.
6–8 months found creatinine to be stable but NAG, albumin,
and retinol-binding protein were underestimated following
storage at −20C, with marked interindividual variation and
36%of samples being substantially affected [27]. Examination
of albumin specifically, in various pathological urine samples
stored for 12 months, also found marked degradation in 11
of 40 samples stored at −20C compared with −70C [28].
Adjustment of the pH to 2.3–2.5 resulted in rapid albumin
degradation consistent with pepsin-type proteolytic activity
and adjustment of pH to neutral and/or addition of PI was
recommended [28].
Although not extensive and patient-dependent (but
consistent within individual patients), our study found more
marked changes in peptides, probably reflecting the relative
impacts of proteolysis with partial degradation of a protein
spot being amplified in terms of the resultant peptide peaks
detected against a low background. It is possible that some of
the differences ±PI may have occurred not during the pro-
cessing period per se as part of a continuous process but dur-
ing subsequent storage at −80C prior to analysis. In the case
of SELDI, the period of storage was approximately 3 months
and for the 2D PAGE analysis result, it was 2 years. How-
ever, we consider this to be the less likely explanation and
this is supported partly by the slightly lower number of peaks
affected in some of the immediately processed (30 min)
samples without PI compared with those delayed for 6 h.
Intuitively, as urine is stored in the bladder, much of the pro-
teolysis would have expected to occur prior to voiding even,
which cannot be prevented and in fact which presumably
underlies the disease-specific signatures of urinary peptides
[7,10,29], but clearly our findings indicate that in some sam-
ples this may be an ongoing process, continuing following
voiding. In the absence of PI (and even in the presence of PI at
longer time delays and dependent on temperature), this may
therefore be variable depending on processing conditions
as indicated and potentially impact the results. The question
of whether this supports addition of PI to samples though
as routine must be considered against the various pros
and cons. PI solutions/tablets are expensive, toxic, and can
interfere with analysis, for example competing with proteins
on SELDI chips depending on the surface chemistry (not the
case in our study as shown in the spiking results) or binding
to/introducing modifications to proteins as previously re-
ported for 4-(2-aminoethyl) benzenesulfonyl fluoride [30]. De-
pending on the model, continued and variable proteolysis in
some samplesmayhaveno impact andmay even just enhance
the proteolytic differences underlying different diseases and
classificationmodels.UsingCE-MSand looking at 1200–2000
peptides per sample [10], derived models using 273 peptides
[7] may not be affected and certainly many technical aspects
have been investigated [7, 31] as part of ongoing studies.
Stability analyses within CE-MS studies examining a delay of
6 h at RT or 24 h at 4C in three patient samples found CE-MS
results were not affected in terms of “statistical spread” or
support vector machine (SVM) scores implying consistent
classification [10], although no further details were provided
about any effects seen on specific peaks. Similarly, storage of
eight samples at 4C for up to 2 wk prior to analysis was not
found to adversely affect their classification in a diagnostic
model [32].
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Figure 8. Continued. (B)–(F) Features shown across the groups, in one gel from each condition of the samples that demonstrated an
alteration in each feature, respectively: (B) 373 in E; (C) 1204 in E; (D) 379 in A; (E) 1191 in D; (F) 685 in D.
Examining much smaller numbers of peptide peaks by
MALDI/SELDI has shown some processing-related effects
with storage at 4C prior to freezing resulting in small
numbers of changes [11, 18] and changes in normal urine
peptide profiles after 6 h at 25C compared with 4C [33]
withmarked interindividual variation. Interestingly, first-void
urine (but not midstream) showed considerable changes fol-
lowing 3 days storage at both 4C and RT, with new peaks
appearing in the 2–6 kDa range [34]. A time-dependent de-
crease in the number of urinary peaks in normal urine sam-
ples over 48 h at RTwas prevented with the addition of PI, but
only over the first 2 hwith progressive changes being reported
at later times even in the presence of PI [19]. This is consis-
tent with our observations using pathological urine samples,
where those with the most marked changes in the absence of
PI also started to show some changes after 6 h in the presence
C©2014TheAuthorsPROTEOMICSClinical ApplicationsPublishedbyWiley-VCHVerlagGmbH&Co.KGaA www.clinical.proteomics-journal.com
520 S. Hepburn et al. Proteomics Clin. Appl. 2015, 9, 507–521
of PI, particularly at RT. The components of the commercial
PI cocktail are proprietary but of the fourmajor classes of pro-
teolytic enzymes (serine, cysteine, metallo-, and aspartic), it
is aimed at inhibition of cysteine and serine proteases. Given
that the pH of all samples was adjusted to neutral to avoid
precipitation [35], it is unlikely that aspartic proteases that
are active at acidic pH are responsible for any of the changes
in peptides we have seen in the presence or absence of PI.
However, the PI cocktail is EDTA-free to avoid issues with
the IMAC chemistry and thereforematrix-metalloproteinases
may account for some of the peptide changes. Certainly, ex-
amples of various matrix metalloproteinases and their com-
plexes have been reported in urine in a variety of diseases
including urinary tract infection, post-renal transplantation
with either acute/chronic rejection or fibrosis, and diabetes
[36–40]. The differences in peaks affected in the presence and
absence of PI, although there is some overlap, are likely to
reflect the differing patterns of activity/inhibition of the var-
ious contributing proteases and therefore different peptide
masses. Unfortunately, the identities of the peptides could
not be determined, which is a major limitation of the SELDI
platform and which has precluded our modeling of possible
proteases involved [29].
Control of analytical and pre-analytical variables is
crucial for the success of urine analysis, in order to obtain
meaningful and reproducible data, even if the interpatient
variability is difficult to avoid. The development of universal
standard operating procedures for sample collection and
handling is a complex task that will require shared expe-
rience and expertise, but this would better facilitate the
future adoption of clinical proteomics into routine hospital
practice.
Overall, our assessment of the impact of processing de-
lays and addition of PIs to urine peptide and protein analysis
has demonstrated that the dominant effects are the inter-
individual variability and underlying pathology. Processing-
related changes to proteins were minimal and althoughmore
marked, changes to peptides in the absence of PIs were very
sample-dependent, with many samples exhibiting no appar-
ent degradation. We would advocate the use of PI where pos-
sible due to the unpredictability of proteolytic activity within
samples but pragmatically, particularly for peptides, thismust
be balanced against the contributions of such activity to any
diagnostic models. The most critical aspect is the adoption of
consistent protocols within studies, their description within
published studies, and the incorporation into any biomarker
validation studies of investigations of potential impact of sam-
ple handling processes.
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